USE OF NELUMBO NUCIFERA LEAF EXTRACT IN PREPARING A PHARMACEUTICAL COMPOSITION FOR THE INCREASE OF ADULT HIPPOCAMPAL NEUROGENESIS
20210346444 · 2021-11-11
Assignee
Inventors
Cpc classification
A61K47/46
HUMAN NECESSITIES
A61K9/0053
HUMAN NECESSITIES
A61P25/28
HUMAN NECESSITIES
International classification
A61K9/00
HUMAN NECESSITIES
Abstract
The present invention provides a composition comprising Nelumbo nucifera leaf extract and a method for the increase of adult hippocampal neurogenesis.
Claims
1. A method of increasing adult hippocampal neurogenesis in a subject, comprising administering a composition comprising an effective amount of Nelumbo nucifera leaf extract to the subject, wherein the Nelumbo nucifera leaf extract is Nelumbo nucifera leaf water extract (NLWE), or Nelumbo nucifera leaf alcoholic extract (NLAE).
2. The method according to claim 1, wherein the Nelumbo nucifera leaf extract increase adult hippocampal neurogenesis by activating BDNF/TrkB/CREB signaling pathway.
3. The method according to claim 1, wherein the composition is a pharmaceutical composition or a food composition.
4. The method according to claim 1, wherein the subject is suffering from a degenerative neurological disease.
5. The method according to claim 4, wherein the degenerative neurological disease is Alzheimer's disease.
6. The method according to claim 4, wherein the degenerative neurological disease is Parkinson's disease.
7. The method according to claim 1, wherein the subject is suffering from dementia.
8. The method according to claim 6, wherein the dementia is caused by neurodegeneration.
9. The method according to claim 6, wherein the dementia is vascular dementia.
10. The method according to claim 1, wherein the subject is human.
11. The method according to claim 10, wherein the effective amount of Nelumbo nucifera leaf water extract is about 0.11-11 g/kg.
12. The method according to claim 10, wherein the effective amount of Nelumbo nucifera leaf alcoholic extract is about 0.011-1.1 g/kg.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
DETAILED DESCRIPTION OF THE INVENTION
[0038] The hippocampus plays a crucial role in the regulation of cognitive abilities. The subgranular zone of the dentate gyrus has the phenomenon of adult neural regeneration until old age, but the incidence of neural regeneration will decrease with age. In the past, studies have confirmed that the effects of promoting neural regeneration in the hippocampus of mice and increasing the proliferation and migration of neural stem cells are to improve neurodegenerative diseases.
[0039] The present invention provides a method of increasing adult hippocampal neurogenesis in the subject, comprising administering a composition comprising an effective amount of Nelumbo nucifera leaf extract to the subject, wherein the Nelumbo nucifera leaf extract is Nelumbo nucifera leaf water extract (NLWE), or Nelumbo nucifera leaf alcoholic extract (NLAE).
[0040] According, the invention provides a use of Nelumbo nucifera leaf extract in preparing a composition for the increase of adult hippocampal neurogenesis, wherein the Nelumbo nucifera leaf extract is Nelumbo nucifera leaf water extract (NLWE), or Nelumbo nucifera leaf alcoholic extract (NLAE).
[0041] According to one aspect of the invention, wherein the Nelumbo nucifera leaf extract composition is a pharmaceutical composition or a food composition.
[0042] In one embodiment, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, adjuvant or excipient. In another embodiment, wherein the food composition is selected from the group consisting of food, beverages, health foods, and dietary supplements.
[0043] In an additional aspect of the invention, the Nelumbo nucifera leaf extract is a Nelumbo nucifera leaf water extract (NLWE). In one embodiment, the Nelumbo nucifera leaf water extract is obtained by grinding dried lotus leaves and then dissolving, filtering, centrifuging, and freeze-dried.
[0044] In an additional further aspect of the invention, the Nelumbo nucifera leaf extract is a Nelumbo nucifera leaf alcoholic extract (NLAE), wherein the Nelumbo nucifera leaf alcoholic extract (NLAE) is obtained by extracting the dried Nelumbo nucifera leaf water extract with an alcohol. In one embodiment, wherein the alcohol is methanol.
[0045] The term “prevention” as used herein refers to delaying the onset of symptoms or reducing the appearance of disease in subjects suffering from the disease, and “treatment” means relieving or improving the symptoms of susceptible subjects.
[0046] The term “subject” as used herein means an animal, especially a mammal. In a preferred embodiment, the term “subject” means “human”.
[0047] As used herein, the term “effective amount” means that the active ingredient is used alone or in combination with other drugs to show the effect of increasing adult hippocampal neurogenesis, and to reduce or prevent neurodegenerative diseases. The effective amount conversion between each animal is that those skilled in the art can easily convert based on the knowledge
[0048] For example, when being administered into a mouse, an effective amount of Nelumbo nucifera leaf water extract (NLWE) is at least approximately 10 g/kg; more preferably, an effective amount of Nelumbo nucifera leaf water extract (NLWE) is approximately from 1 g/kg to 100 g/kg. When being administered into a person, an effective amount of Nelumbo nucifera leaf water extract (NLWE) is at least approximately 1.1 g/kg; more preferably, an effective amount is approximately from 0.11 g/kg to 11 g/kg.
[0049] For example, when being administered into a mouse, an effective amount of Nelumbo nucifera leaf alcoholic extract (NLAE) is at least approximately 1 g/kg; more preferably, an effective amount of Nelumbo nucifera leaf alcoholic extract (NLAE) is approximately from 0.1 g/kg to 10 g/kg. When being administered into a person, an effective amount of Nelumbo nucifera leaf alcoholic extract (NLAE) is at least approximately 0.11 g/kg; more preferably, an effective amount is approximately from 0.01 g/kg to 1.1 g/kg.
[0050] In one aspect of the invention, wherein the subject is suffering from a degenerative neurological disease. In one embodiment, wherein the degenerative neurological disease is Alzheimer's disease. In another embodiment, wherein the degenerative neurological disease is Parkinson's disease.
[0051] In another aspect of the invention, wherein the subject is suffering from dementia. In one embodiment, wherein the dementia is caused by neurodegeneration. In another embodiment, wherein the dementia is vascular dementia.
[0052] In another aspect of the invention, wherein the Nelumbo nucifera leaf extract increase adult hippocampal neurogenesis by increasing DCX protein expression and activating BDNF/TrkB/CREB signaling pathway.
[0053] In another aspect of the invention, the main effective ingredients contained in each mg of Nelumbo nucifera leaf water extract (NLWE) are as follows: 6.11±0.15 μg gallic acid, 7.42±0.69 μg catechin, 3.55±0.04 μg peltatoside, 4.65±0.14 μg rutin, 2.83±50.1 μg isoquercitrin, 8.81±0.18 μg miquelianin, and 0.75±0.05 μg astragalin
[0054] In another aspect of the invention, the main effective ingredients contained in each mg of Nelumbo nucifera leaf alcoholic extract (NLAE) are as follows: 0.37±0.07 μg gallic acid, 24.8±1.84 μg catechin, 0.24±0.04 μg caffeic acid, 0.55±0.08 μg ρ-coumaric acid, 1.30±0.23 μg ferulic acid, 29.07±1.08 μg peltatoside, 8.89±0.34 μg rutin, 50.65±1.24 μg isoquercitrin, 89.05±2.47 μg miquelianin, 3.43±0.24 μg astragalin, 1.20±0.18 μg nuciferine, 6.70±0.18 μg quercitrin, 0.51±0.15 μg naringenin, and 4.7±0.14 μg hesperetin.
EXAMPLES
[0055] Through the following specific embodiments, it can be further proved that the practical application scope of the present invention. It is only a preferred embodiment of the present invention, and does not limit the scope of the present invention. Therefore, any simple changes and modifications made in accordance with the scope of the present invention and the contents of the invention specification are still covered by the scope of the present invention.
[0056] Experimental Materials and Methods
[0057] Preparation of Nelumbo nucifera Leaf Extract
[0058] Preparation of Nelumbo nucifera Leaf Water Extract (NLWE)
[0059] The Nelumbo nucifera leaves were freeze-dried, grinded into powder at 4° C. with a grinder, and stored in a −20° C. freezer. Mix 100 g of dried Nelumbo nucifera leaf powder with 3000 mL of distillation-distillation H.sub.2O (ddH.sub.2O) and stir at 4° C. for one hour. After that, filter the coarse residue by suction filtration, collect the filtrate, and freeze drying to make lotus leaf water extract.
[0060] The main effective ingredients contained in each mg of Nelumbo nucifera leaf water extract (NLWE) are as follows: 6.11±0.15 μg gallic acid, 7.42±0.69 μg catechin, 3.55±0.04 μg peltatoside, 4.65±0.14 μg rutin, 2.83±50.1 μg isoquercitrin, 8.81±0.18 μg miquelianin, and 0.75±0.05 μg astragalin.
[0061] Preparation of Nelumbo nucifera Leaf Alcoholic Extract (NLAE)
[0062] Weigh 100 g of dried NLWE, and mix with 500 ml of methanol at 50° C. water bath for 3 hours. After incubation, collect the filtrate by filter suction. Repeatedly the extract procedures for 3 to 5 times. After completely extraction, concentrate the extract by vacuum concentration. The dried crude Nelumbo nucifera leaf alcoholic extract was reconstituted with 500 ml of ddH.sub.2O, and further mixed with 200 ml of n-hexane to remove the pigment by placing in a separatory funnel. After standing overnight, the aqueous solution was collected and added 180 ml of ethyl acetate which is used to extract the ingredients in the water layer. Mix well and let stand overnight, collect the upper layer solution, and repeat the extraction procedures for 3 to 5 times. By using vacuum concentration method to remove the ethyl acetate, and finally dissolve in 20 ml ddH.sub.2O and vacuum freeze-dried, the resulting powder was Nelumbo nucifera leaves alcoholic extract (NLAE) and stored in the refrigerator at −20° C. Before conducting cell experiments, the powder was dissolved in 50% alcohol solution and then sterile filtered, followed by high performance liquid chromatography (HPLC) analysis of NLAE. The results showed that the main effective ingredients contained in each mg of NLAE were as follows: 0.37±0.07 μg gallic acid, 24.8±1.84 μg catechin, 0.24±0.04 μg caffeic acid, 0.55±0.08 μg ρ-coumaric acid, 1.30±0.23 μg ferulic acid, 29.07±1.08 μg peltatoside 8.89±0.34 μg rutin, 50.65±1.24 μg isoquercitrin, 89.05±2.47 μg miquelianin 3.43±0.24 μg astragalin, 1.20±0.18 μg nuciferine, 6.70±0.18 μg quercitrin 0.51±0.15 μg naringenin, 4.7±0.14 μg hesperetin.
[0063] Animal Feeding and Grouping
[0064] Purchase a 5-week-old male C57BL/6 black mouse from the National Laboratory Animal Center. The weight of the mouse at the time of purchase was about 20 grams. It was kept in the Experimental Animal Center of Chung Shan Medical University. The life cycle is 12 hours of light and 12 hours of darkness, and the time of light is from 6 am to 6 pm. The temperature was maintained at room temperature 22±2° C., and the humidity was 60±5%. After 36 mice were raised to 16 weeks of age, they were randomly divided into control group or drug groups. The drug groups were including NLWE group (the treatment dosage was 10 g NLWE per kg of body weight) and NLAE group (the treatment dosage is 1 g NLAE per kg of weight). Animals in the control group were fed with general feed, while the drug groups mixed NLWE or NLAE into the general feed for mice. After 14-day treatment, the animals were euthanized with carbon dioxide in a high-pressure barrel, and blood was collected from the heart. Perfusion with PBS was used to wash away the whole body blood of the mouse. After the blood was washed, 6 mice from each group were taken for pre-fixation using 4% paraformaldehyde perfusion. After the fixation was completed, the mouse brain was removed. To facilitate follow-up tissue immunostaining and observe the distribution and expression of DCX, NeuN and PCNA in the dentate gyrus of the hippocampus. The other 6 mice in each group took fresh hippocampal tissue for Western blotting after PBS perfusion, and observed the protein expression of DCX, BDNF, TrkB and p-CREB.
[0065] Immunohistochemical Staining
[0066] Embed the mouse brain in paraffin, slice continuously at 3 μm, put it in 38° C. water after cutting, make it fully stretched, and attach it to the center of the coated slide (protein:glycerol is 1:1). Place the slides on a drying table at 38° C. to dry. Dewax with 100% xylene three times in an oven at 65-70° C. for 30 minutes, 5 minutes each time. After dewaxing, return water with high to low concentration alcohol, in order of 100%, 95%, 80%, 75% and ddH.sub.2O, 5 minutes each. Place the slide in citric acid solution (0.01 M, pH=6) and heat to 100° C. in water for 20 minutes for antigen retrieval. After cooling, wash with 0.1% Tween in PBS solution (PBST) 3 times, then react with DAB (3,3′-Diaminobenzidine) color reagent inhibitor for 10 minutes. After the reaction was completed, add the primary antibody of the protein to be detected, act in a humid dark box at 37° C. for 1 hour, then wash with PBST 3 times, and then treat it with horseradish peroxidase multimer at room temperature for 20 minutes. Wash three times with PBST, add equal proportion of DAB coloring agent and DAB hydrogen peroxide (1:1) to make the tissue color for about 1 minute, and wash with ddH.sub.2O for 5 minutes. After dyeing with hematoxylin as the background for 30 seconds, the excess dye has been washed with ddH.sub.2O, and then dehydrated with low to high concentration alcohol (sequentially 70%, 80%, 95%, and 100% alcohol). After 5 minutes, finally immersed in xylene, and then sealed with mounting medium.
[0067] BDNF Quantitative Analysis
[0068] Enzyme-linked immunosorbent assay (ELISA) was used to detect the content of BDNF in serum by following the product manual of the purchased BDNF ELISA kit (ab212166, abcam). First, add 50 μL of mouse serum to the well plate, then add 50 μL of antibody cocktail, seal the plate on a shaker, and react at room temperature for 1 hour. 350 μL wash buffer, PT was washed three times. After washing, excess liquid was removed and 100 μL TMB (3,3′, 5,5′-tetramethylbenzidine) substrate was added and placed on the shaker in the incubator in the dark for 10 minutes, then add 100 μL stop solution, place on a shaker, react at room temperature for 1 minute, and measure the absorbance at 450 nm with an enzyme immunoassay analyzer. At the same time, the human BDNF standard was used to prepare the standard curve, and the content of BDNF in the mouse serum was calculated, and the result unit was expressed in μg/mL.
[0069] In this study, the cell model established by human neuroblastoma SH-SY5Y was used to observe the effect of lotus leaf extract in promoting nerve proliferation.
[0070] Cell Culture
[0071] SH-SY5Y cells were cultured in Dulbecco's modified Eagle medium-high glucose culture medium (DMEM-High glucose, pH 7.2-7.4) with 10% fetal bovine serum (FBS), 1.5 g/L sodium bicarbonate, 2 mM L-glutamine, 1 mM pyruvate Sodium, 0.1 mM non-essential amino acids solution and 1 mM antibiotic (Penicillin/Streptomycin/Amphotericine B, PSA) and placed in a cell incubator with a temperature of 37° C., a humidity of 95%, and 5% CO.sub.2. Change the fresh medium every 2 to 3 days until the cells grow to reach 80 to 90% confluence and then subculture.
[0072] Subculture
[0073] When the cultures reached a confluence of 80˜90%, remove the cultured medium, wash with 5 mL phosphate buffer solution (PBS) 2 times, and then add 2 mL 0.5% trypsin-EDTA to incubate at 37° C. for a few minutes. After incubation, tap the flask to de-attach the cells from the flask, then add 3 mL of the culture solution to stop the reaction, and transfer the de-attached cells to the tube. After centrifugation at 1000 rpm for 5 minutes, remove the supernatant and add 2 ml of fresh culture medium to break up the cells evenly, take 1 mL of cells into a culture flask containing 9 ml of fresh culture medium and continue culturing.
[0074] Cell Survival Analysis
[0075] 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT is a yellow dye that accepts hydrogen ions and acts on the respiratory chain in mitochondria. The principle of MTT is succinate dehydrogenase (SDH) and cytochrome C of the living cells in the mitochondria can convert the tetrazolium bromide of MTT to blue-purple formazan crystals and then deposited in cells. SDH in dead cells is no enzyme activity, and MTT cannot be metabolized and reduced. Therefore, by detecting the absorbance value of the ability of cells to convert yellow-colored MTT to blue/purple formazan crystals can be known to estimate the cell survival rate.
[0076] SH-SY5Y cells were cultured in 96-well dishes (1×10.sup.4 cells/well) for 24 hours, and then treated with different concentrations of NLAE (0, 25, 50, 100 μg/mL). After 24 hours of treatment, remove the cultured medium, add a culture solution containing 0.5 mg/mL MTT for 4-hour incubation. Remove the culture solution after 4 hours of reaction, add 200 μL isopropanol to dissolve the crystal, and read the absorbance at a wavelength of 563 nm by using an enzyme immunoassay analyzer to observe the cell survival rate.
[0077] Cell Proliferation Analysis
[0078] Bromodeoxyuridine (BrdU) is a synthetic nucleoside, which is an analog of thymidine. During DNA replication, it will compete with thymidine to bind to newly synthesized DNA. Further, the BrdU labeled on the DNA is detected by an antibody that can detect BrdU through immunochemical methods, so it can be used to detect the proliferation ability of cells. The BrdU cell proliferation analysis kit used in this research was purchased from Merck Millipore QIA58 and the following experiments were performed according to the user manuals.
[0079] SH-SY5Y cells were incubated in a 96-well dish (1×104 cells/well) for 24 hours, and then simultaneously add 180 μL of different concentrations of NLAE (0, 25, 50, 100 μg/mL) and 20 μL BrdU for 24 hours. After 24 hours of incubation, remove the supernatant and add 200 μl Fixative/Denaturing solution. After standing at 25° C. for 30 minutes, remove the contents and add 100 μL anti-BrdU antibody (according to 1:2000 ratio for dilution), let stand at 25° C. for 1 hour, remove the contents, wash with wash buffer 3 times and add 200 μL peroxidase goat anti-mouse IgG (diluted at 1:2000 ratio) at 25° C. for 30 minutes. After that, remove the contents, wash with wash buffer 3 times, then rinse with ddH.sub.2O. After washing, add 100 μL substrate solution, and keep at 25° C. in the dark for 15 minutes, and then add 100 μL of stop solution to stop the reaction. Use an enzyme immunoassay analyzer to read the absorbance at 450 nm in 30 minutes to observe the cell proliferation.
[0080] Western Blotting
[0081] Mouse hippocampal gyrus protein extraction: Take the hippocampus from the left and right sides of the mouse and add 150 μL of protein lysate (RIPA buffer is used as protein lysate in this study, which includes 50 mM NaCl, 0.5% Deoxycholic acid, 50 mM Tris-Base, 1% NP-40, 1% SDS, 10 μg/mL PMSF, 10 μg/mL Leupeptin, 1% Protease inhibitor, Phosphatase inhibitor, pH7.5) into a glass test tube, grind on ice with a grinder for 5 minutes, and then centrifuge at 12,000 rpm for 20 minutes at 4° C., draw the supernatant into a new tube and store at −20° C. This is the mouse hippocampal protein.
[0082] Cell protein extraction: SH-SY5Y cells were cultured in 75T culture flasks (2.37×10.sup.6 cells/vial) for 24 hours, then treated with different concentrations of NLAE (0, 25, 50, 100 μg/mL) for 24 hours. After 24-hour incubation, wash twice with PBS, add 2 mL of trypsin-EDTA to de-attach cells. Further, add 3 mL of culture medium containing 10% FBS was to neutralize the enzymatic activity of trypsin, and then centrifuged at 1000 rpm for 5 minutes to get the cell pellet. The pellet was washed with PBS and added 100 μL of protein lysis buffer (RIPA buffer), grinded on ice for 3 minutes, and then centrifuged at 12,000 rpm for 20 minute. Take the supernatant and store at −20° C. until analysis.
[0083] The protein extracts of hippocampal tissues or cells of each group were subjected to protein quantification, and each group was diluted to the same concentration according to the result of the quantification, added 5 times sample buffer and mixed uniformly, and heated at 100° C. for 10 minutes. The protein sample to be analyzed is subjected to protein electrophoresis, and then the protein on the gel was transferred to the nitrocellulose membrane through protein transfer. The nitrocellulose membrane was reacted with 5% skim milk at room temperature for 1 hour to block non-specific antigen binding; after that, a primary antibody was added to act at 4° C. overnight, and then washed 3 times with PBST (5 minutes/time), added the secondary antibody for 1 hour at room temperature, washed with PBST 3 times (5 minutes/time), added HRP coloring agent and detected the signal under the illuminometer.
[0084] Statistical Analysis
[0085] The test results of various indicators of animal experiments were first analyzed using Sigma plot 10.0 statistical software. One-way ANOVA was used for analysis, and Duncan's Multiple Range Test was used to compare whether there was a statistically significant difference between the control group and the drug group (p<0.05). The results of the cell experiment were compared with the differences between the groups by Student's t test. When p<0.05, it indicated that there were statistically significant differences.
[0086] Experimental Results
[0087] Effects of NLWE and NLAE on Neurogenesis of SGZ in Hippocampal Dentate Gyrus of Mice
[0088] To observe whether Nelumbo nucifera leaf extract can promote SGZ nerve regeneration in the mouse dentate gyrus, after the mouse sacrifice, take its hippocampus and use immunochemical tissue staining to observe the immature neuron differentiation indicator protein, DCX, the index protein of nucleus of mature neurons, NeuN and cell proliferation index protein, PCNA. The results show that there is no DCX and PCNA expression, but only a small amount of NeuN expression in the hippocampal dentate SGZ of the control group mice. However, there is a significantly increase of DCX, NeuN and PCNA expression in the hippocampal dentate SGZ of mice fed with Nelumbo nucifera leaf extract. Especially, the increased expression is more significantly in mice fed with NLAE. From the above results, it is known that both NLWE and NLAE can effectively promote the neural regeneration of SGZ in the hippocampal dentate gyrus of C57BL/6 mice (
[0089] The Effect of NLWE and NLAE on the Serum BDNF Content in Mice
[0090] BDNF is the main neurotrophic factor in the brain, mainly expressed in the hippocampus, cerebellum and cerebral cortex, and plays an important role in the formation of long-term memory. Previously studies have shown that BDNF can promote the formation of synapses in brain nerve cells, increase synaptic plasticity, promote the proliferation and differentiation of neural stem cells, and resist the damage of harmful factors such as oxidative inflammation to the brain. Therefore, this invention intends to further explore whether NLWE and NLAE can increase the secretion of BDNF to promote neurite regeneration in the hippocampus. The results show that compared with the control group, the BDNF content in the serum of mice fed NLWE or NLAE increased significantly (p<0.05). In addition, the increase in the NLAE group is more significant than in the NLWE group. From the results, we can know that NLWE and NLAE can effectively increase the secretion of BDNF in serum (
[0091] Effects of NLWE and NLAE on Neural Regeneration-Related Proteins in the Hippocampal Gyrus of Mice
[0092] Previous studies have shown that DCX is an important indicator of immature neuronal differentiation, and the BDNF/TrkB/CREB signaling pathway can regulate nerve growth, differentiation, and remodeling. In order to verified the mechanism of NLWE or NLAE in promoting neural regeneration, the expression of neuronal regeneration-related proteins in the hippocampus of mice were evaluated by Western blotting. The results show that the protein expression of DCX, BDNF, TrkB, p-CREB in the hippocampus of mice fed the NLWE and NLAE groups are higher than that of the control group, especially the results of the NLAE group are more significant (
[0093] Toxicity Test of NLAE in Human Neuroblastoma SH-SY5Y Cells
[0094] In order to ensure that the dose of NLAE used would not cause the death of SH-SY5Y cells, in this experiment, SH-SY5Y cells were seeded in 96-well plate (1×10.sup.4 cells/well), after 24 hours of culture, add NLAE of different concentrations (0, 25, 50, 100 μg/mL) for 24 hours, followed by MTT assay for cell viability. The results show that high concentration of NLAE (100 μg/mL) does not cause a decrease in the survival rate of SH-SY5Y cells. However, compared with the control group, the cell survival rate of the NLAE-treated group has a significantly increased trend, and increases as the drug concentration increases. It can be known from the above results that the dose of NLAE selected in this experiment does not cause cell death, but tend to promote cell proliferation (
[0095] The Proliferation Test of NLAE in Human Neuroblastoma SH-SY5Y Cells
[0096] Next, to further evaluate the effects of NLAE on promoting the proliferation of SH-SY5Y cells, cells were grown in 96-well plate (1×10.sup.4 cells/well) for 24 hours, and then added with different concentrations of NLAE (0, 25, 50, 100 μg/ml) and BrdU for 24 hours. Detect the cell proliferation ability by BrdU cell proliferation kit. The results show that the proliferation ability significantly increases in NLAE treatment, which is a dose-dependent manner (
[0097] Effect of NLAE on the Promotion of SH-SY5Y Neural Regeneration Related Protein
[0098] From the above results, it is known that NLAE effectively promotes the proliferation of SH-SY5Y cells, so further analysis of the expression of neuronal neonatal-related proteins to confirm the mechanism of promoting proliferation. Cells were cultured in 75T flask (2.37×10.sup.6 cells/vial) for 24 hours, treated with different concentrations of NLAE (0, 25, 50, 100 μg/ml) for 24 hours, and then observed the expression of neuronal neonatal associated protein by Western blotting. The results show that after treatment of NLAE with SH-SY5Y, the expression of immature neuronal differentiation index protein DCX is higher than that of the control group and the increase is in a dose-dependent manner. As a result, NLAE can promote SH-SY5Y neural regeneration by increasing the performance of DCX (